Search Results for “EC” – Page 153 – media

Enzychem Lifesciences Announces the FDA Orphan Drug Designation Granted to EC-18 on Acute Radiation Syndrome (ARS)

Enzychem Lifesciences, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to EC-18 for the treatment of Acute Radiation Syndrome (ARS).
- Source: china-pharmacy
- 590
- February 1, 2018
ARS EC-18 FDA Orphan Drug Designation rare diseases
NICE becomes latest champion for digital health

NICE has become the latest organisation to champion digital health, recommending that the NHS should trial an online and mobile programme to treat depression.
- Source: Pharma Phorum
- 741
- February 1, 2018
Company Insight digital health EHR NICE
Adverum Biotechnologies and Editas Medicine Extend Research Collaboration

Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced today an extension of its collaboration agreement with Editas Medicine, Inc. (Nasdaq:EDIT). The companies established this collaboration to explore the delivery of genome editing medicines to treat up to five inherited retinal diseases.
- Source: investors.adverum
- 464
- January 31, 2018
genome editing Market Views retinal diseases
FDA steps up efforts at bringing about medical device cyber security

It is a disturbing, but true fact that medical devices are hacked. Medical devices have inbuilt software, and hackers try to breach this. Medical device cybersecurity is thus critical, because lack of it can bring harm to patients who use medical devices that come with software built into them.
- Source: COMPLIANCE4ALL14
- 634
- January 31, 2018
cybersecurity FDA medical device Policy
North Colorado Medical Center invests nearly $2 million in new robotic surgery technology

Maurice Lyons remembers when lung surgery used to require him to make a 6-10 inch incision in a patients' skin and fracture a rib. He'd take the lung out, do what needed to be done and put it back. It would take patients about a week to recover enough just to leave the hospital, Lyons said.
- Source: The Tribune
- 557
- January 30, 2018
Company Insight lung medical device medtech surgery
Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

Novartis AG (NYSE: NVS) today announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approval of its new drug application (NDA) for Lutathera® (lutetium Lu 177 dotatate*) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors, in adults.
- Source: Novartis
- 486
- January 29, 2018
FDA GEP-NETs Lutathera® New Approvals
AstraZeneca’s Three-in-One COPD Inhaler Succeeds in Phase III Trial

AstraZeneca has GlaxoSmithKline and its chronic obstructive pulmonary disease (COPD) treatment Trelegy Ellipta squarely in its sights. This morning, AstraZeneca revealed Phase III data that shows its experimental three-in-one inhaler PT010 improved lung function in patients.
- Source: Biospace
- 581
- January 29, 2018
Clinical Trials COPD inhaler
Cybersecurity for Medical Device Endpoints

With the recent, highly publicized incidents of identity theft, ransomware and malware attacks directed at healthcare facilities, the medical device community is on high-security alert.
- Source: WIBU Systems
- 788
- January 29, 2018
cybersecurity FDA Market Views medical device
Researchers describe receiver-free, glucose-sensing contact lens

A team of South Korean researchers is the latest to tout a smart, glucose-sensing contact lens. In a research article published today in Science Advances, the team described soft lenses carrying a tiny LED light that automatically turns off in the event of high glucose levels, as well as their efforts to test the lens in vivo.
- Source: MobiHealthNews
- 561
- January 26, 2018
blood glucose levels glycemic Researches wearables
AstraZeneca’s PARP Inhibitor Lynparza Gets Approval in Japan

AstraZeneca AZN and partner Merck MRK announced that the Japanese Ministry of Health, Labour and Welfare has granted approval to its PARP inhibitor, Lynparza, as a maintenance therapy for relapsed ovarian cancer, irrespective of BRCA mutation status in patients who have responded to their last platinum-based chemotherapy.
- Source: finance.yahoo
- 672
- January 26, 2018
cancer inhibitor New Approvals ovarian

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.